1375799-59-9 Usage
Description
Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate is a complex organic compound with a unique chemical structure. It is characterized by the presence of a pyrimidine ring, a morpholine group, a 1,2,3-triazole ring, and a pyrazole ring. sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate is synthesized for various applications, particularly in the field of pharmaceuticals and chemical research.
Uses
Used in Pharmaceutical Research:
Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate is used as a key intermediate in the synthesis of new polydentate tetrazole compounds. These compounds are of interest for their potential applications in medicinal chemistry, particularly in the development of novel drugs.
Used in Renal Disease-Induced Anemia Treatment:
Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate is also used in the development of investigational therapies for renal disease-induced anemia. This application is based on its potential to contribute to the development of new treatments for anemia associated with kidney diseases.
Used in Chemical Synthesis:
In the chemical industry, sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate is used as a versatile building block for the synthesis of various complex organic molecules. Its unique structure allows for the creation of a wide range of compounds with diverse properties and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1375799-59-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,5,7,9 and 9 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1375799-59:
(9*1)+(8*3)+(7*7)+(6*5)+(5*7)+(4*9)+(3*9)+(2*5)+(1*9)=229
229 % 10 = 9
So 1375799-59-9 is a valid CAS Registry Number.
1375799-59-9Relevant articles and documents
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia
Beck, Hartmut,Jeske, Mario,Thede, Kai,Stoll, Friederike,Flamme, Ingo,Akbaba, Metin,Ergüden, Jens-Kerim,Karig, Gunter,Keldenich, J?rg,Oehme, Felix,Militzer, Hans-Christian,Hartung, Ingo V.,Thuss, Uwe
, p. 988 - 1003 (2018/04/19)
Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.
Substituted sodium 1H-pyrazol-5-olate
-
, (2012/06/01)
The present application relates to sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1 H-pyrazol-5-olate, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.
